| Literature DB >> 30314382 |
Petri Tähtinen1, Graziano Guella2, Giacomo Saielli3, Cécile Debitus4, Edouard Hnawia5, Ines Mancini6.
Abstract
Arsenicin A (C₃H₆As₄O₃) was isolated from the New Caledonian poecilosclerid sponge Echinochalina bargibanti, and described as the first natural organic polyarsenic compound. Further bioguided fractionation of the extracts of this sponge led us to isolate the first sulfur-containing organic polyarsenicals ever found in Nature. These metabolites, called arsenicin B and arsenicin C, are built on a noradamantane-type framework that is characterized by an unusual As⁻As bonding. Extensive NMR measurements, in combination with mass spectra, enabled the assignment of the structure for arsenicin B (C₃H₆As₄S₂) as 2. The scarcity of arsenicin C and its intrinsic chemical instability only allowed the collection of partial spectral data, which prevented the full structural definition. After the extensive computational testing of several putative structures, structure 3 was inferred for arsenicin C (C₃H₆As₄OS) by comparing the experimental and density functional theory (DFT)-calculated ¹H and 13C NMR spectra. Finally, the absolute configurations of 2 and 3 were determined with a combined use of experimental and time-dependent (TD)-DFT calculated electronic circular dichroism (ECD) spectra and observed specific rotations. These findings pose great challenges for the investigation of the biosynthesis of these metabolites and the cycle of arsenic in Nature. Arsenicins B and C showed strong antimicrobial activities, especially against S. aureus, which is comparable to the reference compound gentamycin.Entities:
Keywords: NMR spectroscopy; antibacterial; arsenical; calculated NMR spectrum; density functional theory; natural products; structure elucidation; sulfur metabolite
Mesh:
Substances:
Year: 2018 PMID: 30314382 PMCID: PMC6212947 DOI: 10.3390/md16100382
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Molecular structures of arsenicin A (C3H6As4O3) (1) and the new arsenicin B (2) and arsenicin C (3). Arbitrary numbering is for convenience.
NMR spectral data for arsenicin B and arsenicin C in CDCl3 (1H at 400 MHz, 13C at 75 MHz, J in Hz). nOe: nuclear Overhauser enhancement.
| C-Atom | δH (ppm), | δC (ppm) | HMBC | nOe |
|---|---|---|---|---|
| Arsenicin B a | ||||
| 1 | Ha 3.96 ( | 42.20 | C-2 | 1-Hb |
| 2 | Ha 3.46 ( | 27.40 | 2-Hb | |
| 3 | Ha 3.44 ( | 25.70 | 3-Hb | |
| Arsenicin C | ||||
| 1 | Ha 3.50 ( | 45.14 | 1-Hb | |
| 2 | Ha 2.99 ( | 31.40 | C-1 | 2-Hb |
| 3 | Ha 3.27( | 33.58 | 3-Hb | |
a from Lu et al., 2015 [21]: 1H NMR (300 MHz, CDCl3): δ 1.57 (d, J 13.5), 1.93 (d, J 13.5), 2.35 (d, J 12.3) 3.45 (dd, J 13.5, 1.8), 3.47 (dd, J 13.5, 1.8 Hz), 3.97 (d, J 12.3 Hz); 13C NMR (126 MHz, CDCl3): δ 25.9, 27.4, 42.3.
Figure 2Trial structures for arsenicin B. B1 and B2 feature four-membered and six-membered-rings; B3–B5 feature a seven-membered ring; B6–B9 feauture only five-membered and six-membered rings. Structure B2 is computationally unstable, and evolves to B2’ upon optimization (see text). The bonds indicated by dashed lines in B1 are not fully occupied, as shown by a natural bond orbital (NBO) analysis calculation.
Experimental and calculated 1H and 13C chemical shifts (ppm) for structure B6 of arsenicin B. C and H descriptors are given according to the numbering in Figure 1. Definitions of methods (A)–(C) are presented in Section 3.4.
| Nucleus | Exptl | (A) | (B) | (C) |
|
|---|---|---|---|---|---|
| C1 | 42.20 | 57.57 | 59.47 | 58.44 | 6.66 |
| C2 | 27.40 | 42.57 | 44.05 | 41.40 | 7.37 |
| C3 | 25.70 | 41.00 | 42.26 | 39.40 | 6.75 |
| H1a | 3.96 | 3.35 | 3.32 | 3.99 | −0.37 |
| H1b | 2.34 | 1.98 | 1.96 | 2.41 | −0.25 |
| H2a | 3.46 | 3.00 | 2.99 | 3.46 | −0.24 |
| H2b | 1.92 | 1.49 | 1.49 | 2.00 | −0.28 |
| H3a | 3.44 | 2.92 | 2.89 | 3.26 | −0.30 |
| H3b | 1.56 | 1.15 | 1.15 | 1.49 | −0.20 |
| MAE (13C) | 15.28 | 16.83 | 14.65 | ||
| MAE (1H) | 0.46 | 0.48 | 0.07 | ||
| MAE (all) | 5.40 | 5.93 | 4.93 | ||
| 1.0 | 1.0 | 1.2 | |||
| 15.0 | 15.5 | 9.8 | |||
| R(13C) | 0.9999 | 0.9999 | 0.9999 | ||
| 0.93 | 0.92 | 0.98 | |||
| −0.26 | −0.25 | 0.05 | |||
| R(1H) | 0.9983 | 0.9981 | 0.9948 |
a The correlation between the experimental and calculated values is represented by a linear equation: δcalcd = aδexptl + b.
Figure 3Trial structures considered for arsenicin C in NMR computational analysis.
Energies of trial structures C1–C3 of arsenicin C by density functional theory (DFT) calculation at a B3LYP/6-311G (2d,2p) level of theory.
| Structure | Δ | |
|---|---|---|
| C1 | −9535.03540580 | 1.5 |
| C2 | −9535.03778732 | 0.0 |
| C3 | −9535.03662772 | 0.7 |
Experimental and calculated 1H and 13C chemical shifts (ppm) for the candidate structures C1 and C2 of arsenicin C. H descriptors 1a–3b in brackets are given according to the numbering in Figure 1. Definitions of methods (A)–(C) are reported in Section 3.4.
| Nucleus | Exptl | C1 | C2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| (A) | (B) | (C) | σSO | (A) | (B) | (C) | σSO | ||
| C1 | 45.14 | 50.38 | 52.04 | 54.93 | 3.30 | 57.67 | 59.70 | 59.90 | 5.09 |
| C2 | 31.40 | 43.25 | 44.90 | 40.87 | 8.90 | 44.16 | 45.84 | 44.27 | 5.96 |
| C3 | 33.58 | 46.37 | 47.96 | 45.82 | 5.97 | 47.04 | 48.69 | 46.62 | 6.01 |
| H1a | 3.50 | 2.93 | 2.92 | 3.52 | −0.22 | 2.98 | 2.98 | 3.59 | −0.31 |
| H1b | 2.02 | 1.70 | 1.69 | 2.08 | −0.23 | 1.60 | 1.62 | 2.25 | −0.35 |
| H2a | 2.99 | 2.94 | 2.93 | 3.52 | −0.30 | 2.62 | 2.63 | 3.03 | −0.16 |
| H2b | 1.44 | 1.17 | 1.17 | 1.66 | −0.31 | 0.96 | 0.99 | 1.65 | −0.38 |
| H3a | 3.27 | 3.39 | 3.38 | 3.72 | −0.22 | 2.90 | 2.88 | 3.24 | −0.23 |
| H3b | 1.29 | 1.01 | 1.03 | 1.45 | −0.20 | 0.78 | 0.80 | 1.38 | −0.34 |
| MAE (13C) | 9.96 | 11.59 | 10.50 | 12.92 | 14.70 | 13.56 | |||
| MAE (1H) | 0.27 | 0.27 | 0.24 | 0.44 | 0.43 | 0.12 | |||
| MAE (all) | 3.50 | 4.04 | 3.66 | 4.60 | 5.19 | 4.60 | |||
| 0.5 | 0.5 | 1.0 | 1.0 | 1.0 | 1.1 | ||||
| 29.7 | 31.3 | 12.5 | 14.3 | 15.1 | 8.4 | ||||
| R (13C) | 0.9543 | 0.9574 | 0.9788 | 0.9984 | 0.9988 | 0.9999 | |||
| 1.04 | 1.03 | 1.06 | 1.03 | 1.01 | 0.93 | ||||
| −0.32 | −0.29 | 0.09 | −0.51 | −0.46 | 0.26 | ||||
| 0.9730 | 0.9724 | 0.9815 | 0.9978 | 0.9979 | 0.9963 | ||||
Experimental and calculated JH,H values (in Hz) for the candidate structures C1 and C2 of arsenicin C, according to the computational methods (A)–(C), defined as in Section 3.4.
| Exptl | C1 | C2 | |||||
|---|---|---|---|---|---|---|---|
| (A) | (B) | (C) | (A) | (B) | (C) | ||
|
2
| 12.8 | −8.73 | −11.50 | −6.58 | −8.90 | −11.65 | −6.82 |
|
2
| 13.7 | −9.80 | −12.69 | −7.52 | −9.87 | −12.70 | −7.69 |
|
2
| 13.8 | −9.83 | −12.79 | −7.65 | −9.70 | −12.61 | −7.54 |
|
4
| 1.52 | 1.27 | 0.60 | 1.61 | 1.46 | 0.74 | |
|
4
| −0.20 | −0.11 | −0.29 | −0.26 | −0.16 | −0.37 | |
|
4
| −0.34 | −0.29 | −0.43 | −0.21 | −0.11 | −0.32 | |
|
4
| 1.7 | −0.38 | −0.06 | −0.09 | 0.26 | 0.71 | 0.48 |
|
4
| 1.9 | 0.04 | 0.52 | 0.31 | 0.36 | 0.91 | 0.57 |
|
4
| −0.74 | −0.61 | −0.66 | −0.37 | −0.18 | −0.35 | |
|
4
| −0.80 | −0.70 | −0.70 | −0.48 | −0.32 | −0.45 | |
|
4
| 1.02 | 0.99 | 0.60 | 1.54 | 1.59 | 0.96 | |
|
5
| −0.08 | 0.15 | 0.26 | −0.16 | 0.06 | 0.24 | |
|
5
| −0.90 | −0.83 | −0.58 | −0.81 | −0.72 | −0.47 | |
|
5
| −0.89 | −0.79 | −0.51 | −0.84 | −0.73 | −0.52 | |
|
5
| −1.03 | −0.95 | −0.60 | −1.03 | −0.95 | −0.64 | |
| MAE ( | 3.1 | 1.3 | 4.4 | 3.0 | 1.1 | 4.2 | |
a Involves only 2J(H1a,H1b), 2J(H2a,H2b), 2J(H3a,H3b), 4J(H1b,H2b), and 4J(H2a,H3a).
Figure 4Experimental (a) and calculated (b) 1H spectra of arsenicin C and structure C2, respectively. Spectrum recorded in CDCl3 at 400 MHz.Chemical shifts calculated with method (C), couplings with method (B). Simulations at 400 MHz.
Antimicrobial activities reported as inhibition diameters in mm for arsenicin B (2) and C (3), in comparison with arsenicin A, and to gentamycin when used as a control test sample.
| Compound | Weight |
|
|
|
|---|---|---|---|---|
| Arsenicin A a | 10 μg/disc | 24 | 28 | 26 |
| 5 μg/disc | 23 | n.t. | 23 | |
| 1 μg/disc | 19 | 17 | 12 | |
| Arsenicin B | 10 μg/disc | 15 | n.t. b | 13 |
| 5 μg/disc | 14 | n.t. | 12 | |
| 1 μg/disc | 10 | n.t. | n.t. | |
| Arsenicin C | 10 μg/disc | 21 | 12 | 16 |
| 5 μg/disc | 20 | n.t. | 9 | |
| 1 μg/disc | 10 | 7 | n.t. | |
| Gentamycin | 10 μg/disk | 22 | 30 | 22 |
a data already reported by Mancini et al., 2006 [15]. b n.t.: not tested (compounds obtained in minute quantities).